Key result
Celecoxib was cost-effective compared to nonselective NSAIDs in 60-year-old osteoarthritis patients, with a base model incremental cost-effectiveness ratio of $31,097 per quality-adjusted life-year gained.
Why the study?
Does celecoxib improve incremental costs per quality-adjusted life-year (QALY) gained in 60-year-old patients with moderate to severe osteoarthritis (OA) requiring chronic daily NSAIDs?
Population
60-year-old patients with moderate to severe osteoarthritis requiring chronic daily NSAIDs, with average…
Comparison
Celecoxib 200 mg/d vs Nonselective nonsteroidal anti-inflammatory…
Design
Other
Follow-up
21 years (lifetime analytic horizon)
Authors
Loading...
Supports celecoxib as an economically viable option for older osteoarthritis patients; extends prior safety.
Does celecoxib improve incremental costs per quality-adjusted life-year (QALY) gained in 60-year-old patients with moderate to severe osteoarthritis (OA) requiring chronic daily NSAIDs?
Effect estimate: ICER $31,097 per QALY
In a decision analysis model, chronic celecoxib therapy was found to be cost-effective compared to nonselective NSAIDs in 60-year-old osteoarthritis patients with average upper gastrointestinal risks.
Loyd et al. (2007) studied Osteoarthritis. Celecoxib vs. Nonselective NSAIDs (diclofenac 100 mg/d and naproxen 1000 mg/d) was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER $31,097 per QALY). Celecoxib was cost-effective compared to nonselective NSAIDs in 60-year-old osteoarthritis patients, with a base model incremental cost-effectiveness ratio of $31,097 per quality-adjusted life-year gained.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: